|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LIF |
Gene summary for LIF |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LIF | Gene ID | 3976 |
| Gene name | LIF interleukin 6 family cytokine | |
| Gene Alias | CDF | |
| Cytomap | 22q12.2 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P15018 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3976 | LIF | P21T-E | Human | Esophagus | ESCC | 2.23e-02 | 2.90e-01 | 0.1617 |
| 3976 | LIF | P57T-E | Human | Esophagus | ESCC | 2.26e-03 | 6.81e-01 | 0.0926 |
| 3976 | LIF | P74T-E | Human | Esophagus | ESCC | 1.79e-05 | 1.04e-01 | 0.1479 |
| 3976 | LIF | P75T-E | Human | Esophagus | ESCC | 7.01e-08 | 3.69e-01 | 0.1125 |
| 3976 | LIF | P76T-E | Human | Esophagus | ESCC | 1.52e-10 | 6.13e-01 | 0.1207 |
| 3976 | LIF | P83T-E | Human | Esophagus | ESCC | 3.19e-20 | 1.07e+00 | 0.1738 |
| 3976 | LIF | P130T-E | Human | Esophagus | ESCC | 1.15e-02 | 2.11e-01 | 0.1676 |
| 3976 | LIF | GSM5252134_BPH511PrG_Fcol_3GEX | Human | Prostate | BPH | 2.79e-03 | 5.63e-01 | -0.1433 |
| 3976 | LIF | GSM5252135_BPH511PrPUr_Fcol_3GEX | Human | Prostate | BPH | 5.90e-08 | 8.82e-01 | -0.1833 |
| 3976 | LIF | 047563_1562-all-cells | Human | Prostate | BPH | 1.89e-02 | 2.56e-01 | 0.0791 |
| 3976 | LIF | 048752_1579-all-cells | Human | Prostate | BPH | 4.61e-05 | 1.95e-01 | 0.1008 |
| 3976 | LIF | Dong_P1 | Human | Prostate | Tumor | 7.45e-29 | 4.30e-01 | 0.035 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00987276 | Prostate | BPH | maintenance of cell number | 43/3107 | 134/18723 | 7.29e-06 | 1.04e-04 | 43 |
| GO:00198275 | Prostate | BPH | stem cell population maintenance | 42/3107 | 131/18723 | 9.49e-06 | 1.33e-04 | 42 |
| GO:00507695 | Prostate | BPH | positive regulation of neurogenesis | 63/3107 | 225/18723 | 1.11e-05 | 1.51e-04 | 63 |
| GO:00507678 | Prostate | BPH | regulation of neurogenesis | 92/3107 | 364/18723 | 1.36e-05 | 1.78e-04 | 92 |
| GO:00510516 | Prostate | BPH | negative regulation of transport | 113/3107 | 470/18723 | 1.76e-05 | 2.18e-04 | 113 |
| GO:00720737 | Prostate | BPH | kidney epithelium development | 42/3107 | 136/18723 | 2.62e-05 | 3.10e-04 | 42 |
| GO:00025739 | Prostate | BPH | myeloid leukocyte differentiation | 58/3107 | 208/18723 | 2.76e-05 | 3.24e-04 | 58 |
| GO:19030253 | Prostate | BPH | regulation of RNA polymerase II regulatory region sequence-specific DNA binding | 9/3107 | 13/18723 | 3.55e-05 | 3.90e-04 | 9 |
| GO:001063916 | Prostate | BPH | negative regulation of organelle organization | 87/3107 | 348/18723 | 3.56e-05 | 3.90e-04 | 87 |
| GO:00075656 | Prostate | BPH | female pregnancy | 54/3107 | 193/18723 | 4.64e-05 | 4.87e-04 | 54 |
| GO:00607063 | Prostate | BPH | cell differentiation involved in embryonic placenta development | 13/3107 | 25/18723 | 5.04e-05 | 5.21e-04 | 13 |
| GO:004340915 | Prostate | BPH | negative regulation of MAPK cascade | 51/3107 | 180/18723 | 5.20e-05 | 5.35e-04 | 51 |
| GO:00604255 | Prostate | BPH | lung morphogenesis | 20/3107 | 50/18723 | 6.88e-05 | 6.78e-04 | 20 |
| GO:00181059 | Prostate | BPH | peptidyl-serine phosphorylation | 79/3107 | 315/18723 | 7.09e-05 | 6.96e-04 | 79 |
| GO:00064733 | Prostate | BPH | protein acetylation | 55/3107 | 201/18723 | 7.69e-05 | 7.42e-04 | 55 |
| GO:00183943 | Prostate | BPH | peptidyl-lysine acetylation | 48/3107 | 169/18723 | 7.96e-05 | 7.65e-04 | 48 |
| GO:00447066 | Prostate | BPH | multi-multicellular organism process | 59/3107 | 220/18723 | 8.01e-05 | 7.66e-04 | 59 |
| GO:00720016 | Prostate | BPH | renal system development | 76/3107 | 302/18723 | 8.55e-05 | 8.09e-04 | 76 |
| GO:00018225 | Prostate | BPH | kidney development | 74/3107 | 293/18723 | 9.31e-05 | 8.76e-04 | 74 |
| GO:19021058 | Prostate | BPH | regulation of leukocyte differentiation | 71/3107 | 279/18723 | 9.94e-05 | 9.21e-04 | 71 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0466810 | Esophagus | ESCC | TNF signaling pathway | 89/4205 | 114/8465 | 3.36e-10 | 4.01e-09 | 2.06e-09 | 89 |
| hsa0466817 | Esophagus | ESCC | TNF signaling pathway | 89/4205 | 114/8465 | 3.36e-10 | 4.01e-09 | 2.06e-09 | 89 |
| hsa046688 | Prostate | BPH | TNF signaling pathway | 41/1718 | 114/8465 | 6.86e-05 | 4.35e-04 | 2.69e-04 | 41 |
| hsa0466815 | Prostate | BPH | TNF signaling pathway | 41/1718 | 114/8465 | 6.86e-05 | 4.35e-04 | 2.69e-04 | 41 |
| hsa0466821 | Prostate | Tumor | TNF signaling pathway | 40/1791 | 114/8465 | 3.88e-04 | 2.07e-03 | 1.29e-03 | 40 |
| hsa0466831 | Prostate | Tumor | TNF signaling pathway | 40/1791 | 114/8465 | 3.88e-04 | 2.07e-03 | 1.29e-03 | 40 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| OSM | LIFR_IL6ST | OSM_LIFR_IL6ST | OSM | Breast | DCIS |
| LIF | LIFR_IL6ST | LIF_LIFR_IL6ST | LIFR | Breast | Healthy |
| OSM | LIFR_IL6ST | OSM_LIFR_IL6ST | OSM | Breast | Healthy |
| LIF | LIFR_IL6ST | LIF_LIFR_IL6ST | LIFR | Cervix | ADJ |
| OSM | LIFR_IL6ST | OSM_LIFR_IL6ST | OSM | Cervix | CC |
| LIF | LIFR_IL6ST | LIF_LIFR_IL6ST | LIFR | Cervix | CC |
| OSM | LIFR_IL6ST | OSM_LIFR_IL6ST | OSM | Cervix | Precancer |
| LIF | LIFR_IL6ST | LIF_LIFR_IL6ST | LIFR | Endometrium | ADJ |
| OSM | LIFR_IL6ST | OSM_LIFR_IL6ST | OSM | Endometrium | ADJ |
| LIF | LIFR_IL6ST | LIF_LIFR_IL6ST | LIFR | Endometrium | AEH |
| OSM | LIFR_IL6ST | OSM_LIFR_IL6ST | OSM | Endometrium | AEH |
| OSM | LIFR_IL6ST | OSM_LIFR_IL6ST | OSM | Endometrium | EEC |
| LIF | LIFR_IL6ST | LIF_LIFR_IL6ST | LIFR | Endometrium | EEC |
| LIF | LIFR_IL6ST | LIF_LIFR_IL6ST | LIFR | Endometrium | Healthy |
| OSM | LIFR_IL6ST | OSM_LIFR_IL6ST | OSM | Endometrium | Healthy |
| OSM | LIFR_IL6ST | OSM_LIFR_IL6ST | OSM | Esophagus | ESCC |
| LIF | LIFR_IL6ST | LIF_LIFR_IL6ST | LIFR | Esophagus | ESCC |
| OSM | LIFR_IL6ST | OSM_LIFR_IL6ST | OSM | HNSCC | ADJ |
| OSM | LIFR_IL6ST | OSM_LIFR_IL6ST | OSM | HNSCC | Healthy |
| OSM | LIFR_IL6ST | OSM_LIFR_IL6ST | OSM | HNSCC | OSCC |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| LIF | SNV | Missense_Mutation | rs753939297 | c.451G>A | p.Val151Met | p.V151M | P15018 | protein_coding | tolerated(0.09) | probably_damaging(0.997) | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| LIF | SNV | Missense_Mutation | c.102T>G | p.Cys34Trp | p.C34W | P15018 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-AR-A0TP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| LIF | SNV | Missense_Mutation | novel | c.344N>G | p.Ser115Cys | p.S115C | P15018 | protein_coding | deleterious(0.01) | possibly_damaging(0.627) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
| LIF | SNV | Missense_Mutation | novel | c.343N>A | p.Ser115Thr | p.S115T | P15018 | protein_coding | deleterious(0.02) | benign(0.029) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
| LIF | SNV | Missense_Mutation | rs140799590 | c.218N>T | p.Pro73Leu | p.P73L | P15018 | protein_coding | deleterious(0.03) | probably_damaging(1) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| LIF | SNV | Missense_Mutation | c.514N>T | p.Thr172Ser | p.T172S | P15018 | protein_coding | tolerated(0.58) | benign(0.023) | TCGA-G4-6293-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | fluorouracil | SD | |
| LIF | SNV | Missense_Mutation | novel | c.576G>T | p.Lys192Asn | p.K192N | P15018 | protein_coding | tolerated(0.08) | probably_damaging(0.996) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| LIF | SNV | Missense_Mutation | novel | c.575A>C | p.Lys192Thr | p.K192T | P15018 | protein_coding | tolerated(0.14) | probably_damaging(0.996) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| LIF | SNV | Missense_Mutation | novel | c.143N>G | p.Ile48Ser | p.I48S | P15018 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
| LIF | SNV | Missense_Mutation | rs746660268 | c.421N>A | p.Ala141Thr | p.A141T | P15018 | protein_coding | tolerated(1) | benign(0.015) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 3976 | LIF | GROWTH FACTOR, DRUGGABLE GENOME | RETINOIC ACID | 2119291 | ||
| 3976 | LIF | GROWTH FACTOR, DRUGGABLE GENOME | HORMONES | 11589623 | ||
| 3976 | LIF | GROWTH FACTOR, DRUGGABLE GENOME | BUPIVACAINE | BUPIVACAINE | 10838161 | |
| 3976 | LIF | GROWTH FACTOR, DRUGGABLE GENOME | CLOMIPHENE CITRATE | 12012626 | ||
| 3976 | LIF | GROWTH FACTOR, DRUGGABLE GENOME | PACLITAXEL | PACLITAXEL | 11800022 | |
| 3976 | LIF | GROWTH FACTOR, DRUGGABLE GENOME | IL-13 | 12620497 | ||
| 3976 | LIF | GROWTH FACTOR, DRUGGABLE GENOME | SIMVASTATIN | SIMVASTATIN | 16797728 | |
| 3976 | LIF | GROWTH FACTOR, DRUGGABLE GENOME | CISPLATIN | CISPLATIN | 11800022,12519017 | |
| 3976 | LIF | GROWTH FACTOR, DRUGGABLE GENOME | MIFEPRISTONE | MIFEPRISTONE | 10717784 | |
| 3976 | LIF | GROWTH FACTOR, DRUGGABLE GENOME | OESTRADIOL | ESTRADIOL | 10508216 |
| Page: 1 2 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |